Sermorelin vs Ipamorelin: The Real Differences

Sermorelin and ipamorelin get sold as interchangeable "GH peptides," usually side by side on the same telehealth page, and the comparison is almost always framed as a matter of taste — one is gentler, one is cleaner, pick whichever your clinic pushes. That framing hides the two things that actually separate them.

The direct answer: sermorelin and ipamorelin are not two versions of the same drug. Sermorelin is GHRH(1-29), a fragment of your own growth-hormone-releasing hormone that works at the GHRH receptor; ipamorelin is a synthetic pentapeptide that mimics ghrelin at a completely different receptor, the growth-hormone secretagogue receptor. They pull two different levers on the same axis. And the evidence behind them is lopsided: sermorelin was an FDA-approved drug product with published pediatric and elderly trial data, while ipamorelin's human record amounts to a small pharmacology study in healthy volunteers and one phase 2 trial that missed its endpoint and was not carried forward. Neither has a controlled trial showing it improves athletic performance, and both are prohibited in tested sport.

Two Different Receptors, Not Two Strengths of the Same Thing

Growth hormone release from the pituitary is governed by more than one input, and these two peptides hit different ones.

Sermorelin is GHRH(1-29) — a 29-amino-acid analog of human growth-hormone-releasing hormone, described in the drug literature as the shortest synthetic peptide carrying the full biological activity of GHRH¹. It binds the GHRH receptor and amplifies the signal your hypothalamus already sends. Because it works upstream, the pituitary's own feedback control stays in the loop; that is the mechanistic argument clinics make when they call it more "physiologic."

Ipamorelin is a pentapeptide secretagogue built from a chemistry program that stripped down an earlier GH-releasing peptide, and its pharmacology places it firmly at the GHRP-type receptor rather than the GHRH receptor⁵. That receptor is the one identified in pituitary and hypothalamus in 1996 as functioning in growth-hormone release¹¹ — and whose natural ligand turned out, in 1999, to be ghrelin, the stomach-derived acylated peptide¹⁰. So ipamorelin is a ghrelin mimic. Everything odd about the GH-secretagogue class, including appetite effects and off-target pituitary hormones in its older relatives, traces back to that receptor. We cover the earlier generation in GHRP-2 vs GHRP-6 vs hexarelin.

The practical consequence of "different receptors" is not that one is stronger. It is that the two do not substitute for each other cleanly, and that a comparison of them is a comparison of two mechanisms with very different amounts of human data behind them.

What Sermorelin Actually Did in People

Sermorelin's evidence is the part most comparisons skip, and it is genuinely the deeper of the two — with the important caveat that it was studied in patients, not athletes.

In growth-hormone-deficient children, a multicenter study of 110 previously untreated prepubertal patients gave 30 micrograms per kilogram of GHRH(1-29) once daily at bedtime for up to a year. Mean height velocity rose from 4.1 cm/year at baseline to 8.0 cm/year at six months and 7.2 cm/year at twelve, with 74% of children rated good responders at six months². A drug review of sermorelin summarized the same picture and noted the honest limit: height-velocity gains on sermorelin were smaller than those in children given daily somatropin, and the effect on final adult height was undetermined¹.

In older adults — the population telehealth sermorelin is actually marketed to — there are two informative studies with different answers. Healthy old men given GHRH(1-29) subcutaneously twice daily for 14 days showed dose-related increases in 24-hour GH secretion and in IGF-1, with the high dose bringing them to levels not significantly different from young men³. But a six-week study using a single nightly injection in healthy men aged 64 to 76 raised nocturnal GH release without changing IGF-1, IGFBP-3, weight, body-mass index, or the DEXA measures of muscle and fat; two of six strength tests improved⁴. Read together, those two results say something specific: the hormone response depends on the dosing pattern, and a rise in GH did not reliably deliver a body-composition change. That is the same gap we track in does sermorelin actually help athletes, the underlying trial record in sermorelin athletic recovery evidence, and the expectation-setting in sermorelin before and after.

What Ipamorelin Actually Did in People

Ipamorelin's human file is short, and being precise about it matters.

Its famous result — selectivity — is preclinical. The 1998 paper that introduced it as the first selective GH secretagogue tested rat pituitary cells, anesthetized rats, and conscious swine. In the swine work, GHRP-6 and GHRP-2 both raised ACTH and cortisol while ipamorelin did not, at doses more than 200-fold above the level needed for half its GH effect, and none of the secretagogues tested moved FSH, LH, prolactin, or TSH⁵. That is a real and impressive finding. It is also a finding in pigs, and the "no cortisol, no prolactin" line repeated on sales pages rarely says so.

In humans, ipamorelin has a dose-escalation pharmacology study: five infusion rates, eight healthy male subjects at each level, showing dose-proportional kinetics, a terminal half-life of about two hours, and a single episode of GH release peaking around 40 minutes and then declining⁶. That establishes that it releases GH in people. It does not establish an outcome.

The outcome attempt is the part the marketing omits. Ipamorelin was developed as a ghrelin-receptor agonist for postoperative ileus — sluggish bowel after abdominal surgery — and reached a phase 2, multicenter, double-blind, placebo-controlled trial in bowel-resection patients. Of 114 evaluable patients, intravenous ipamorelin was well tolerated, and there were no significant differences between ipamorelin and placebo on the key endpoint (median time to first tolerated meal 25.3 versus 32.6 hours, p = 0.15) or on the secondary analyses⁷. That program did not go on to approval. So the randomized outcome trial ipamorelin is best known for in the published literature is a negative one, in a use that has nothing to do with muscle, and there is no approved ipamorelin product anywhere. The safety detail is in ipamorelin side effects.

Why Do Clinics Tell You to Stack Them?

Because there is a real pharmacology finding underneath the pitch — and it is older and narrower than the pitch implies.

In 1990, Bowers and colleagues gave 18 normal men a synthetic GH-releasing peptide alone and together with GHRH. Submaximal doses of the peptide plus GHRH stimulated GH release synergistically, which the authors read as evidence that the two act through independent systems⁸. Later controlled work in men mapped what determines the size of that GHRH-plus-GHRP synergy⁹. So "a GHRH analog plus a secretagogue releases more GH than either alone" is not marketing invention; it is measured human endocrinology.

Two limits keep it from being a recommendation. First, those studies used acute GH release as the endpoint — not muscle, not recovery, not fat mass. Second, the specific pairing sold today is usually CJC-1295 with ipamorelin rather than sermorelin with ipamorelin, and the version of the synergy tested in the lab was neither. A review of secretagogues in men with hypogonadism, covering sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin together, reaches the same place: these compounds are potent GH and IGF-1 stimulators, and the clinical data examining what that does for patients is what is missing¹⁴. The stack itself is covered in ipamorelin + CJC-1295, and the DAC question that changes the dosing entirely in CJC-1295 DAC vs no DAC.

The Availability Gap Is the Biggest Practical Difference

This is where "different lever, same axis" stops being academic.

Our peptide regulatory tracker records the two compounds in different sections entirely, and the wording matters. Ipamorelin is listed as a category 2 compound under FDA's 503B interim policy, with its 503A nomination separately withdrawn — appearing in both tables, with neither one amounting to a lawful compounding basis, and with FDA citing a published report of serious adverse events including death after intravenous administration. Sermorelin sits in a different group: an FDA-approved drug product containing sermorelin acetate exists on the record (Geref, NDA 019863 and NDA 020443), every presentation is marked discontinued, and FDA formally determined the product was not discontinued or withdrawn for safety or effectiveness reasons — the clause a compounding pharmacy relies on. The tracker is equally clear on what that does not mean: no sermorelin presentation is currently marketed, and compounded sermorelin is not an FDA-approved drug.

In plain terms, sermorelin has a route to a prescription and a compounding pharmacy that ipamorelin does not, which is why telehealth sermorelin is a purchasable subscription and ipamorelin tends to arrive through gray-market channels or a clinic willing to ignore the tables. That is the single most consequential difference between them for a buyer.

What Sermorelin Costs When You Can Buy It

Since sermorelin is the one with a purchase path, the pricing distinction is worth stating in the terms we verify. The number in an advertisement and the number you pay each month are frequently different figures, and our price transparency index exists because of it.

Two verified examples. At Invigor Medical, sermorelin injection is priced per strength — $220.50 for 8 mg, $270.50 for 15 mg, $310.50 for 20 mg, with consult and supplies included — but the billing runs every four weeks rather than monthly, which is thirteen charges in a calendar year and about $2,866 for the entry strength rather than the $2,640 a monthly reading implies; the Invigor Medical review shows the arithmetic. At Maximus, the $199.99 figure carried across the site is the six-month plan; a single month is $299.99, and the subscription terms state that a committed plan is not eligible for early termination or a partial refund — detailed in the Maximus review. Per-provider rows are on our best sermorelin providers rankings, checked as of August 2026.

Do Either of Them Help an Athlete?

No controlled trial says so for either compound, and the evidence on the hormone they both raise argues against expecting much.

A systematic review of randomized trials of growth hormone in physically fit people aged 13 to 45 — 27 study samples, 303 participants receiving GH — found that lean body mass increased by about 2.1 kg, but strength and exercise capacity did not appear to improve, exercise lactate was higher in two of three studies measuring it, and soft-tissue edema and fatigue were more common on GH¹². A randomized, placebo-controlled trial in 96 recreationally trained athletes reached the same conclusion from the other direction¹³. If administered GH itself does not deliver performance, a peptide whose entire proposition is releasing somewhat more of your own GH is starting from a weak premise. That is the through-line of GH peptides and recovery, peptides for muscle growth, and sermorelin for muscle growth.

Both are also prohibited in tested sport. Sermorelin falls under GHRH analogs, alongside CJC-1295 and tesamorelin; ipamorelin falls under GH-releasing peptides. Anti-doping laboratories have spent more than a decade refining the assays that detect small peptides like these in athlete samples¹⁵. Check any compound against the current list with our WADA prohibited checker, and read the legal framing in are GH peptides safe and legal.

The Honest Verdict

If the question is which is better, the answer depends on which question you are asking.

On mechanism, they are not competitors — GHRH receptor versus ghrelin receptor, and the two combined release more GH acutely than either alone⁸. On human evidence, sermorelin is clearly ahead: an approved product history, controlled pediatric data², and adult endocrine studies³⁴, against ipamorelin's healthy-volunteer pharmacology⁶ and a phase 2 trial that missed its endpoint⁷. On regulatory footing, sermorelin has a compounding basis and ipamorelin does not. On proven athletic benefit, they tie at zero, and both are banned in tested sport.

Anything involving a prescription peptide is a conversation to have with a clinician who can see your labs; dosing specifics for the one with an actual prescribing history are in our sermorelin dosage guide, and the wider category comparison sits in peptides for recovery and healing, MK-677 evidence, and our evidence-ranked best recovery peptides.